Media headlines about Regeneron Pharmaceuticals (NASDAQ:REGN) have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.9006396427152 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- P Roy Vagelos Sells 74,710 Shares of Regeneron Pharmaceuticals Inc (REGN) Stock (americanbankingnews.com)
- Noteworthy Friday Option Activity: GPC, KMX, REGN (nasdaq.com)
- Did Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Create Value For Shareholders? (finance.yahoo.com)
- Regeneron Is Leading the Way for Biotech (realmoneypro.thestreet.com)
- Inovio announces commencement of Phase 1/2 study of triplet therapy in brain cancer; shares up 1% (seekingalpha.com)
Several equities analysts recently commented on the company. BidaskClub downgraded Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 9th. Leerink Swann set a $435.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 4th. Credit Suisse Group set a $420.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, May 5th. BTIG Research reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 13th. Finally, ValuEngine downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $426.88.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $5.08 by ($0.41). Regeneron Pharmaceuticals had a return on equity of 29.92% and a net margin of 23.54%. The business had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter last year, the business posted $2.92 EPS. The company’s quarterly revenue was up 14.6% on a year-over-year basis. analysts predict that Regeneron Pharmaceuticals will post 17.2 EPS for the current year.
In related news, Director George L. Sing sold 7,000 shares of the stock in a transaction on Wednesday, May 9th. The stock was sold at an average price of $285.29, for a total value of $1,997,030.00. Following the sale, the director now owns 127,772 shares in the company, valued at $36,452,073.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Sanofi sold 121,601 shares of the stock in a transaction on Friday, June 8th. The stock was sold at an average price of $309.31, for a total value of $37,612,405.31. The disclosure for this sale can be found here. Insiders sold 214,718 shares of company stock worth $67,470,695 in the last quarter. 12.42% of the stock is currently owned by company insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.